tbuckley/cabot-search huggingface dataset:
96P Prevalence of hypothyroidism among breast cancer patients treated with radiation to the supraclavicular field: A single center survey
Authors: Y. Kikawa, H. Kato, Y. Kosaka, K. Hashimoto, E. Hohokabe, S. Takebe, K. Ueki, K. Ogura, T. Imagunbai, M. Kokubo
Journal: Annals of Oncology (2016)
Enhancing Graft-vs-Tumor (GVT) Activity of Donor Leukocyte Infusions by Ex-Vivo Expansion and Activation with CD3/CD28 Co-Stimulation.
Authors: David Porter, Bruce Levine, Nancy Bunin, Edward Stadtmauer, Selina Luger, Steven Goldstein, Stephen Schuster, Donald Tsai, Sunita Nasta, Alison Loren, Alexander Perl, Julie Oliver, Ambika Sohal, Liz Veloso, Stephen Emerson, Carl June
Journal: Blood (2004)
BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without <i>MGMT</i> promoter methylation.
Authors: Jeffrey J. Raizer, Pierre Giglio, Jethro Lisien Hu, Morris D. Groves, Ryan Merrell, Charles A. Conrad, Surasak Phuphanich, Vinay K. Puduvalli, Monica Elena Loghin, Nina Paleologos, W. K. Alfred Yung, Brian D. Vaillant, Jeremy David Rudnick, Marc C. Chamberlain, Nicholas Vick, Sean Aaron Grimm, Ivo Tremont-Lukats, John Frederick De Groot, Kenneth D. Aldape, Mark R. Gilbert
Journal: Journal of Clinical Oncology (2013)

2019^ Background: Patients (pts) with GBM with unmethylated MGMT have a worse prognosis than those with methylated MGMT. Novel approaches for this poor risk group are warranted. The Brain Tumor Trials Collaborative (BTTC) performed a phase II trial evaluating standard chemoradiation followed by bevacizumab and erlotinib in patients with MGMT unmethylated GBM. EGFR and VEGFR are upregulated during radiation suggesting that this combination could be more effective than post-radiation adjuvant temozolomide (TMZ). Methods: After informed consent, adult patients with supratentorial GBM, KPS ≥ 70 and &gt; 1 cm 2 tumor block for MGMT promoter analysis were screened. Only tumors with confirmed unmethylated MGMT promoter were enrolled. All patients received RT + TMZ and then approximately 4 weeks after RT they received bevacizumab 10 mg/kg every 2 weeks and erlotinib 150 mg/day, continuously. One cycle was 4 weeks; evaluation by MRI was every 2 cycles. Treatment continued until disease progression or intolerable adverse events. Results: 115 patients were screened; 48 were enrolled (2 unevaluable: 1 for an infratentoral GBM and 1 withdrew after 7 days of treatment) with 29 men, 17 women. Median age was 56 yrs (29-75); median KPS was 90 (70-90). The median number of cycles was 8 (2-38) with 4 patients remaining on trial at the time of analysis. Objective responses: 4 CR, 12 PR and 30 SD. Median PFS is 7.3 months (95% CI (6.4, 11)) and median OS 14.2 months (95% CI (10.7, not reached)). There were no unexpected toxicities; grade 3/4 rate &lt; 5%. Conclusions: Adjuvant bevacizumab and erlotinib in GBM with unmethylated MGMT is well tolerated. Preliminary efficacy data is comparable with outcomes in similar unmethylated MGMT patient populations from the EORTC/NCIC and RTOG 0525 studies. Tissue correlation is being performed. Clinical trial information: NCT00720356.
94P Influence of different treatment planning techniques on radiation doses to the heart, left anterior descending coronary artery and lungs in the radiotherapy of left-sided breast cancer patients
Authors: F. Hadjilooei, P. Haddad, B. Kalaghchi, F. Amouzgar Hashemi, M. Esfahani, H. Nedaie, S. Shahriaran, M. Babaei, F. Farhan
Journal: Annals of Oncology (2016)
Erratum: Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The Dual V randomized clinical trial (JAMA - Journal of the American Medical Association (2016) 315: 9 (898-907))
Authors: Ildiko Lingvay, F. P. Manghi, P. García-Hernández
Journal: JAMA (2016)
What Surgeons Need to Know About Gender Confirmation Surgery When Providing Care for Transgender Individuals
Authors: Jens U. Berli, Gail Knudson, Lin Fraser, Vin Tangpricha, Randi Ettner, Frederic M. Ettner, Joshua D. Safer, Julie Graham, Stan Monstrey, Loren Schechter
Journal: JAMA Surgery (2017)

In 2014, the US Department of Health and Human Services decided that its 1981 exclusion of transsexual surgical treatments from Medicare coverage was based on outdated, incomplete, and biased science and did not reflect current evidence or standards of care, and the exclusion was therefore lifted. As a direct result of this decision, surgeons nationwide are seeing an increase in consultations for surgical therapy to help transgender and gender-nonconforming individuals. Although some clinicians may have the technical training for such surgical procedures, in many cases, they may not have a full understanding of the complex and comprehensive care required to provide optimal health care for transgender individuals.Gender confirmation surgery is a developing field in the United States and other areas of the world. The World Professional Association for Transgender Health started a global education initiative intended to provide surgeons and other health care professionals with the necessary background knowledge to understand and treat this patient population. This article provides an overview of best practices as set forth in the seventh edition of the Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People by the World Professional Association for Transgender Health, including mental health, endocrinology, and surgery for trans women and trans men.Experts in each aspect of transgender health have summarized the content of the global education initiative in this article. It provides valuable information to surgeons of all disciplines and other health care professionals to help guide the treatment and management of transgender individuals.
Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.
Authors: Jürgen Krauter, Gerhard Heil, Dieter Hoelzer, Oliver Ottmann, Hans Martin, Michael Lübbert, Jürgen Finke, Wolf Heit, Walter Fiedler, Dieter Hossfeld, Lothar Kanz, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Arnold Ganser
Journal: Blood (2004)
Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)
Authors: U. Anido, M.J. Juan Fita, L. Munielo-Romay, B. Pérez-Valderrama, B. Mellado, M. Ochoa de Olza, O. Fernandez Calvo, D. Castellano, E.M. Fernandez Parra, M. Domenec, S. Hernando, J. Arranz Arija, C. Caballero, I. Duran, M. Campayo, M.A. Climent
Journal: Annals of Oncology (2016)
Safety, Tolerability and Efficacy of Cat-Peptide Antigen Desensitisation (Cat-PAD) in Cat-Allergic Children – Findings from a Pilot Study
Authors: Stephen Pawsey, Rod P. Hafner, Thomas B. Casale, Piotr Kuna, Bernadetta Majorek-Olechowska, Irena Wojciechowska, Wojciech Wasiak
Journal: Journal of Allergy and Clinical Immunology (2017)
Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts) Age 80 and Older: Analysis of the Veterans Health Administration (VHA) National Database
Authors: Kenneth R. Carson, Ryan Lynch, Peter Riedell, Ryan P. Roop, Arun Ganti, Weijan Liu, Chadi Nabhan, Tanya Wildes, Kristen M. Sanfilippo, Graham A Colditz
Journal: Blood (2012)
METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)
Authors: P. Schmid, M. Melisko, D.A. Yardley, K. Blackwell, A. Forero, G. Ouellette, Y. He, R.G. Bagley, J. Zhang, L.T. Vahdat
Journal: Annals of Oncology (2016)
Group 2 Innate Lymphoid Cells Are Increased in Nasal Polyps in Patients with Eosinophilic Chronic Rhinosinusitis
Authors: Ichiro Tojima, Hideaki Kouzaki, Shino Shimizu, Takao Ogawa, Masahiko Arikata, Hirohito Kita, Takeshi Shimizu
Journal: Journal of Allergy and Clinical Immunology (2017)
Randomized Placebo-Controlled Multicenter Clinical Trial of Wheat Oral Immunotherapy
Authors: Anna H. Nowak-Wegrzyn, Robert A. Wood, Kari C. Nadeau, Jacqueline A. Pongracic, Alice Henning, Kirsten Beyer, Robert W. Lindblad, Hugh A. Sampson
Journal: Journal of Allergy and Clinical Immunology (2017)
Novel Homozygous VHL Mutation in Exon 2 (413C&gt;T:P138L) Is Associated with Congenital Polycythemia, Elevated Level of RUNX1/AML1 Transcript, but Not with the Cancer.
Authors: Lucie Piterkova, Felipe R Lorenzo V, Hari Vankalayapati, Richard A. Drachtman, Josef T. Prchal
Journal: Blood (2012)
Multiple pregnancies may increase a woman’s risk of atrial fibrillation
Authors: Jacqui Wise
Journal: BMJ (2017)

Having multiple pregnancies increases a woman’s risk of developing atrial fibrillation in later life, data from the Women’s Health study published in the journal Circulation have suggested.1

Women who had four or more pregnancies were found to be 30-50% more likely to develop atrial fibrillation than women with no pregnancies, the study of 34 639 women found.

Participants in the study had a median age of 53, had a median of two prior pregnancies, and were healthy at the start of the study. During a median follow-up of 20.5 years the study identified …
Changes in relative conditional survival (RCS) in de novometastatic urothelial carcinoma (mUC): A Surveillance, Epidemiology, and End Results (SEER) database analysis.
Authors: Sumanta Kumar Pal, Nicholas J. Vogelzang, Rebecca A. Nelson
Journal: Journal of Clinical Oncology (2014)

314 Background: Currently, no agents are FDA approved for second-line treatment of mUC. Still, many patients receive second-line treatment, with data from phase II studies used as justification for payors. While this practice may not prolong disease-specific survival (DSS) for all mUC patients, assessing RCS may better account for benefit from 2 nd line treatment. Methods: The SEER database was queried to compare DSS and 1-year RCS rates in de novo mUC patients diagnosed from 1994-2000 (T1) to those diagnosed from 2001-2009 (T2). The cut-off at 2000 was chosen to account for treatment variations stemming from phase II second-line trials published subequent to this date. DSS rates for T1 and T2 were modeled using Kaplan-Meier methods and compared using the log-rank test. 1-year RCS was computed annually from diagnosis through 5-years post diagnosis. The results were age standardized and compared across time periods using the z-test statistic, with 95% confidence intervals calculated using the log(log()) transformation. Multivariate Cox proportional hazard models were used to assess independent prognostic factors of DSS. Results: A total of 4,465 mUC patients were included, with 1,155 diagnosed during T1 and 3,310 diagnosed during T2. Mean age of the overall cohort was 70, and the majority of patients had poorly differentiated or undifferentiated tumors. Median DSS was 6 months for both T1 and T2 groups (P=NS). 1-year RCS rates at 1, 2, and 3 years post diagnosis, were 46%, 71%, and 76% for T1 patients compared to 39%, 68% and 78% for T2 patients (P=NS for each comparison). On MVA, older age (&gt;65) and undifferentiated histology were independently associated with shorter DSS, while use of radiation and surgery were associated with longer DSS. Time period of diagnosis (T1 vs T2), however, had no impact on DSS. Conclusions: Multiple published phase II studies emerging over the past decade have been used to justify use of post second-line therapies for mUC to payors. In contrast to DSS, our assessment of RCS should better account for the impact of these therapies. The lack of improvement in RCS calls into question the impact post first-line therapies have on the natural history of mUC.
Childhood obesity plans already show progress, minister claims
Authors: Adrian O’Dowd
Journal: BMJ (2017)

Early signs of progress on tackling childhood obesity in England have been achieved despite initial disappointment about the government’s strategy, MPs have been told.

MPs on the parliamentary health committee challenged the government on its plans to reduce childhood obesity during an evidence session held on 7 February as a follow-up to its previous inquiry on childhood obesity.

The government’s childhood obesity plan,1 published last August, was criticised at the time by doctors’ leaders, national charities, and campaign groups as being watered down and underwhelming.2 Instead of introducing anticipated restrictions on junk food advertising and promotions, it focused on greater physical activity in schools and a voluntary scheme for the food …
Pattern of microbial organisms in radiation induced mucositis and dermatitis in head and neck squamous cell carcinoma (HNSCC) treated with radiation (RT)/chemo radiation (CTRT).
Authors: Bhanu Prasad Venkatesulu, Supriya Mallick, Pradeep Ventrapati, Vikas Roshan, Suman Bhasker, Goura Kisor Rath
Journal: Journal of Clinical Oncology (2014)

210 Background: Mucositis and dermatitis complicated by bacterial and fungal infections are common in patients undergoing RT/CTRT. We intended to assess spectrum of microbial organisms in skin and oral swabs, rationality of antibiotics/anti-fungal (AB/F), toxicities, hospitalization and treatment delays. Methods: This was a prospective, single arm observational study conducted in a tertiary care hospital. 25 patients undergoing RT or CTRT from January 2014 to June 2014 were included. Patients were subjected to skin-wound and oral swab gram stain, potassium hydroxide mount, bacterial and fungal culture with sensitivity. Results: Median age was 54 years (30-69). Male: female ratio 1.5:1. Primary site: tongue 5 (20%), palate 5 (20%), tonsil, pyriform-sinus 4 (16%) each, buccal-mucosa, alveolus 2 (8%) each, EAC, nasopharynx, RMT one each (12%). 24 2D (96%) and 1 (4%) 3D planning. Feeding tube required for one (4%). 16 received concurrent cisplatin (40mg/m2 weekly), median 3 cycles. At median dose 48 (16-68 Gy) patients were referred for toxicities. Grade III,IV dermatitis were in 5(20%), 1(4%) respectively.Grade III,IV mucositis was 5(20%), 0(0%) respectively. Median laboratory parameters: hemoglobin 10.5, TLC 6350, albumin3.6 and globulin 2.8. Spectrum of organisms isolated is tabulated below. In GPC, specific isolate was Methicillin sensitive staphylococcus aureus 2, beta hemolytic streptococcus one. Four required i.v antibiotics. 3 received i.v ciprofloxacin 200mg BD and i.v metronidazole 500mg TDS, one required i.v cefoperazone-sulbactam 2 gm BD (7 days); rest 21 had adequate relief with topical antibiotics (metronidazole TDS) or antifungal (clotrimazole mouth paint TDS) alone for 7 days. Median duration of hospital stay was 10 days (2-16). Treatment interruption was in 6 ranging 6-10 days. Conclusions: Topical AB/F with adequate hydration can provide adequate symptom relief and avoid treatment interruption for mucositis and dermatitis. [Table: see text]
The Venezuelan Type of Nondeletional Hereditary Persistence of Fetal Hemoglobin Is Due C →T Mutation at Nucleotide -211 of the Aγ Globin Gene.
Authors: Anabel Arends, Martha Bravo Urquiola, Silvia Montilla, Gloria García Lic, Dalia Velásquez De L., Maritza Alvarez, Natalie Gerard, Rajagapol Krishnamoorthy
Journal: Blood (2004)
Subgroup analysis in RAISE: a phase III study of FOLFIRI + ramucirumab or placebo in patients with advanced mCRC
Authors: Takako Nakajima, Josep Tabernero, Eric Van Cutsem, Radka Obermannova, György Bodoky, Jana Prausová, Rocio Garcia-Carbonero, Tudor Ciuleanu, Pilar Garcia Alfonso, David Portnoy, Allen Cohn, Kentaro Yamazaki, Phil Clingan, Takayuki Yoshino, Sara Lonardi, Ling Yang, Federico Nasroulah
Journal: Annals of Oncology (2016)
An IT-integrated, computer-based telephone system for monitoring patient-reported symptoms: Result of two trials.
Authors: Kathi Mooney, Susan L. Beck, Bob Wong, William A. Dunson, Debra Wujcik
Journal: Journal of Clinical Oncology (2012)

2 Background: An automated remote monitoring system of patient reported symptoms was tested in two separate trials to determine if it improved unrelieved symptoms after outpatient chemotherapy. Methods: In Study 1,250 patients and Study 2,335 patients beginning a chemotherapy course were randomized to Telephone Care (TC) (n 129/174) or usual care (UC) (n 121/162). All called daily reporting presence, severity, and distress (0-10 scale) for 11 common symptoms. Those in the Study 1 TC group had reports of moderate to severe symptoms emailed to their oncologist and oncology nurse. Those in Study 2 TC group had similar moderate to severe symptom reports sent to a study Nurse Practitioner (NP) who responded by telephone utilizing evidence based guidelines to intensify symptom care. These patients also received automated tailored self-care messages based on their specific symptoms. Results: The majority of participants in both studies were white (91%; 84%) and female (76%; 77%). The mean age was 56 years, with breast cancer most common (40%; 45%). Mean study days were 45 (Study 1) and 73 (Study 2) with 66% and 87% call completion days respectively. Fatigue, pain, poor sleep, nausea and depressed mood were reported as moderate to severe by over 50% of patients in both studies. In Study 1 no difference was found in symptom severity between TC and UC. Oncology providers found the TC symptom alerts useful but rarely initiated symptom care intensification. In Study 2 the TC group mean symptom score was significantly lower than UC, p &lt; .001. Poisson regression showed TC had fewer Severe symptom days than UC (est. means and SE) 3.16 (0.44) vs. 10.24 (1.84), p &lt; .001; and fewer Moderate days 8.91 (1.04) vs. 19.06 (2.22), p &lt; .001. TC had somewhat higher Mild days 19.85 (2.81) vs. 13.75 (1.85), p = .06; and more no symptom days 66.06 (3.82) vs 52.02 (4.15), p = .01. Conclusions: Remote monitoring of patient reported symptoms after chemotherapy is effective in identifying unrelieved symptoms. It can be used to track quality improvement as well as augment symptom care. Follow up to intensify symptom treatment utilizing guidelines is necessary to achieve significant reductions in symptom severity, distress and days of moderate or severe symptoms.
Immuno Haematological Reconstitution after T-Cell-Depleted HLA-Haploidentical Stem Cell Transplantation for Thalassemia.
Authors: Antonella Isgrò, Buket Erer, Pietro Sodani, Paola Polchi, Marco Marziali, Wilma Leti, Claudia Gramiccioni, Wladimiro De Santis, Massimo Campagna, Giorgia Del Giudice, Maria Caterina Sirianni, Fernando Aiuti, Guido Lucarelli
Journal: Blood (2006)
Adverse Cytogenetics, with or without Trisomies, in Patients Undergoing High Dose Therapy for Multiple Myeloma and Impact of Post-Transplant Maintenance Therapy
Authors: Gregory P Kaufman, Morie A Gertz, Angela Dispenzieri, Martha Q Lacy, Francis K Buadi, David Dingli, Suzanne R Hayman, Prashant Kapoor, S. Vincent Rajkumar, Shaji Kumar
Journal: Blood (2014)
Pegfilgrastim Provides Effective Primary Prophylaxis Against Febrile Neutropenia in Patients with NHL Undergoing Chemotherapy: Initial Results from an Integrated Analysis - The Neulasta Versus Current Neutropenia Management Practice (Neucup) Project.
Authors: Ruth Pettengell, Tomas Skacel, Matti Aapro, Ulrich Duehrsen, Valerie Easton, Gary Lyman
Journal: Blood (2006)
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
Authors: Jiahuai Tan, Lance K. Heilbrun, Joseph A. Fontana, Daryn Smith, Elisabeth I. Heath, Karen Baranowski, Ulka N. Vaishampayan
Journal: Journal of Clinical Oncology (2012)

415 Background: Pazopanib is an oral tyrosine kinase inhibitor and is currently approved for treatment of patients with advanced or mRCC in the first-line, or second-line setting, after progression on cytokine therapy. No reports of efficacy and safety are available post targeted therapy. We conducted a retrospective analysis of cases receiving pazopanib after failure of other targeted agents. Methods: The study was reviewed and approved by our Institutional Review Board. Review of medical records of advanced renal cancer patients, treated with second-line pazopanib from April 2010 to August 2011 at Karmanos Cancer Center was performed. The Common Terminology Criteria for Adverse Events version 4.0 was used to grade the severity of definitely treatment-related adverse events (AEs). Results: 14 patients are included to date in this ongoing data collection and analysis study. Median age was 58 years, 8 were Caucasian, 4 African American, and 2 other races. By the MSKCC criteria, 1 patient was favorable, 6 were intermediate and 7 poor risk. Pazopanib was utilized as second line in 4 patients, third line in 5, and even later in 5. Prior line targeted therapies included sunitinib (8), temsirolimus (9), everolimus (4), sorafenib (1), bevacizumab (1) and axitinib (1). Nine of 14 patients to date were treated with pazopanib for at least 2 months and were assessed for response by imaging studies. One achieved partial remission; 5 had stable disease, and 3 had progression. The median time to progression after starting pazopanib was 4.0 months. The predominant AEs were grade 1 or 2, which included fatigue (4), liver enzyme elevation (3), diarrhea (2), hypertension (2), skin rash (1), depression (1) and hyponatremia (1). No grade 3 or 4 AEs, or definitely treatment-related deaths were observed. Conclusions: Pazopanib appears to maintain efficacy and tolerability in mRCC even after failure of other targeted therapies. Further investigations of larger patient cohorts in this setting are recommended.
Impact of Bone Marrow Plasmacytosis on Outcome in Patients with AL Amyloidosis Following Autologous Stem Cell Transplant
Authors: Yi L. Hwa, Shaji K. Kumar, Martha Q. Lacy, Morie A. Gertz, Francis Buadi, S. Vincent Rajkumar, Ronald S. Go, Nelson Leung, Prashant Kapoor, David Dingli, Stephen J. Russell, John A. Lust, Suzanne R. Hayman, Taxiarchis Kourelis, Angela Dispenzieri
Journal: Blood (2015)
Dietary Intake, Inflammation And Mucosal Integrity In Adult Patients With Eosinophilic Esophagitis
Authors: Berber Vlieg-Boerstra, Marlou de Kroon, Marijn Warners, Marleen Van Ampting, Lucien Harthoorn, Simone Eussen, Arjan Bredenoord
Journal: Journal of Allergy and Clinical Immunology (2017)